Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): A multicentre randomized controlled study

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Rutten, Marianne J ^a   Gaarenstroom, Katja N ^b   Van Gorp, Toon ^c   van Meurs, Hannah S ^a   Arts, Henriette J G ^d   Bossuyt, Patrick M ^a   Ter Brugge, Henk G ^e   Hermans, Ralph H M ^f   Opmeer, Brent C ^a   Pijnenborg, Johanna M A ^g   Schreuder, Henk W R ^h   Schutter, Eltjo M J ⁱ   Spijkerboer, Anje M ^a   Wensveen, Celesta W M ^j   Zusterzeel, Petra ^k   Mol, Ben Willem J ^a   Kenter, Gemma G ^a   Buist, Marrije R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e ISALA HOSPITAL   (Netherlands)

^f CATHARINA HOSPITAL   (Netherlands)

^g CPRLab   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ MEDISCH SPECTRUM TWENTE   (Netherlands)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; HUMAN; INTENTION TO TREAT ANALYSIS; LAPAROSCOPIC SURGERY; LAPAROSCOPY; LAPAROTOMY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NETHERLANDS; OUTCOME ASSESSMENT; OVARY CANCER; PREDICTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; OVARY TUMOR; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LAPAROSCOPY; MIDDLE AGED; NEOPLASM, RESIDUAL; NETHERLANDS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84856017023     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-31     Document Type: Article

References (23)

1. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011, 8:CD007565.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259. 10.1200/JCO.20.5.1248, 11870167.
3. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009, 115:1234-1244. 10.1002/cncr.24149, 19189349.
4. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998, 69:103-108. 10.1006/gyno.1998.4955, 9600815.
5. Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, Kooi GS, Burger CW. Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer 2010, 46:102-109. 10.1016/j.ejca.2009.10.017, 19900801.
6. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010, 363:943-953. 10.1056/NEJMoa0908806, 20818904.
7. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004, 351:2489-2497. 10.1056/NEJMoa041125, 15590951.
8. Dowdy SC, Mullany SA, Brandt KR, Huppert BJ, Cliby WA. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 2004, 101:346-352. 10.1002/cncr.20376, 15241833.
9. Ferrandina G, Sallustio G, Fagotti A, Vizzielli G, Paglia A, Cucci E, et al. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Br J Cancer 2009, 101:1066-1073. 10.1038/sj.bjc.6605292, 2768100, 19738608.
10. Jung DC, Kang S, Kim MJ, Park SY, Kim HB. Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer. Eur Radiol 2009, 20:100-107.
11. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000, 89:1532-1540. 10.1002/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO;2-A, 11013368.
12. Axtell AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007, 25:384-389. 10.1200/JCO.2006.07.7800, 17264334.
13. Salani R, Axtell A, Gerardi M, Holschneider C, Bristow RE. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2008, 108:271-275. 10.1016/j.ygyno.2007.11.004, 18164380.
14. Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol 2011, 124:10-14.
15. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. Eur J Cancer 2011, 47(Suppl 3):S88-S92.
16. Fagotti A, Fanfani F, Ludovisi M, Lo VR, Bifulco G, Testa AC, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol 2005, 96:729-735. 10.1016/j.ygyno.2004.11.031, 15721418.
17. Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006, 13:1156-1161. 10.1245/ASO.2006.08.021, 16791447.
18. Brun JL, Rouzier R, Uzan S, Darai E. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol Oncol 2008, 110:354-359. 10.1016/j.ygyno.2008.04.042, 18572226.
19. Gerestein CG, Eijkemans MJ, de JD, van der Burg ME, Dykgraaf RH, Kooi GS, et al. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG 2009, 116:372-380. 10.1111/j.1471-0528.2008.02033.x, 19187369.
20. Vergote IB, De WI, Decloedt J, Tjalma W, Van GM, van DP. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000, 27:31-36.
21. Fagotti A, Ferrandina G, Fanfani F, Garganese G, Vizzielli G, Carone V, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol 2008, 199:642-646.
22. Jansen FW, Kapiteyn K, Trimbos-Kemper T, Hermans J, Trimbos JB. Complications of laparoscopy: a prospective multicentre observational study. Br J Obstet Gynaecol 1997, 104:595-600. 10.1111/j.1471-0528.1997.tb11539.x, 9166204.
23. Chi DS, Abu-Rustum NR, Sonoda Y, Awtrey C, Hummer A, Venkatraman ES, et al. Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. Am J Obstet Gynecol 2004, 191:1138-1145. 10.1016/j.ajog.2004.05.004, 15507933.